立体定向体部放疗治疗寡转移肝病:预处理化疗与组织学对局部肿瘤控制的影响
基于德国放射肿瘤学会多中心数据库,分析452次SBRT治疗363例患者的肝转移灶,采用脆性模型评估组织学与SBRT前化疗对肿瘤控制概率的影响。校正组织学后,BEDmax是TCP最强预测因子,PTV体积大、SBRT前化疗和简单运动管理技术预测TCP显著降低。无化疗时2年90%TCP需BED 209±67Gy10,有化疗时需286±78Gy10;乳腺癌转移灶所需BEDmax更低。
要点
- 校正组织学后,BEDmax是肝转移SBRT肿瘤控制概率的最强预测因子。
- SBRT前化疗、较大PTV体积和简单运动管理技术预测局部TCP显著降低。
- 乳腺癌肝转移对SBRT反应优于其他组织学,所需BEDmax更低。
核心结论
- 除剂量外,组织学和SBRT前化疗是影响肝转移局部TCP的重要因素。
- 校正化疗后,乳腺癌转移对大分割SBRT反应优于其他组织学。
研究设计与样本
- 多中心数据库回顾性分析452次SBRT治疗363例肝转移患者。
- 组织学通过半参数和参数脆性模型中的随机效应考虑,剂量参数化为BEDmax(α/β=10Gy)。
主要发现
- 校正组织学后,BEDmax是TCP最强预测因子。
- 较大PTV体积、SBRT前化疗和简单运动管理技术预测TCP显著降低。
- 无化疗时2年90%TCP需BED 209±67Gy10,有化疗时需286±78Gy10。
- 乳腺癌转移2年90%TCP所需BEDmax为有化疗157±80Gy10、无化疗80±62Gy10。
关键数值与推荐
- 无化疗时2年90%TCP所需BED为209±67Gy10,有化疗时为286±78Gy10。
- 乳腺癌转移2年90%TCP所需BEDmax为有化疗157±80Gy10、无化疗80±62Gy10。
临床怎么用
- 肝转移SBRT计划时应考虑组织学和SBRT前化疗对TCP的影响。
- 乳腺癌肝转移可能从较低BEDmax的大分割SBRT中获得良好局部控制。
- 对有SBRT前化疗史的患者,可能需要更高BEDmax以达到相同TCP。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Stereotactic body radiation therapy (SBRT) is applied in the oligometastatic setting to treat liver metastases. However, factors influencing tumor control probability (TCP) other than radiation dose have not been thoroughly investigated. Here we set out to investigate such factors with a focus on the influence of histology and chemotherapy prior to SBRT using a large multi-center database from the German Society of Radiation Oncology. METHODS: 452 SBRT treatments in 363 patients were analyzed after collection of patient, tumor and treatment data in a multi-center database. Histology was considered through random effects in semi-parametric and parametric frailty models. Dose prescriptions were parametrized by conversion to the maximum biologically effective dose using alpha/beta of 10Gy (BEDmax). RESULTS: After adjusting for histology, BEDmax was the strongest predictor of TCP. Larger PTV volumes, chemotherapy prior to SBRT and simple motion management techniques predicted significantly lower TCP. The model predicted a BED of 209±67Gy10 necessary for 90% TCP at 2years with no prior chemotherapy, but 286±78Gy10 when chemotherapy had been given. Breast cancer metastases were significantly more responsive to SBRT compared to other histologies with 90% TCP at 2years achievable with BEDmax of 157±80Gy10 or 80±62Gy10 with and without prior chemotherapy, respectively. CONCLUSIONS: Besides dose, histology and pretreatment chemotherapy were important factors influencing local TCP in this large cohort of liver metastases. After adjusting for prior chemotherapy, our data add to the emerging evidence that breast cancer metastases do respond better to hypofractionated SBRT compared to other histologies.
引用
- Klement RJ, Guckenberger M, Alheid H, et al. Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol. 2017. PMID: 28274491. doi:10.1016/j.radonc.2017.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。